Drugs Made In America Acquisition Corp
DMAA
39 hedge funds and large institutions have $232M invested in Drugs Made In America Acquisition Corp in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
5% more funds holding
Funds holding: 37 → 39 (+2)
2.63% more ownership
Funds ownership: 64.91% → 67.55% (+2.6%)
4% more capital invested
Capital invested by funds: $223M → $232M (+$8.63M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCS
Mercuria Capital Strategies
Houston,
Texas
|
+$7.74M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$3.44M |
| 3 |
QL
Quarry LP
New York
|
+$2.59M |
| 4 |
GL
Governors Lane
New York
|
+$2.47M |
| 5 |
CS
Clear Street
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$3.1M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2.58M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.59M |
| 4 |
JP Morgan Chase
New York
|
-$515K |
| 5 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
26
Bulldog Investors
Saddle Brook,
New Jersey
| $1.35M | – | – | – |
|
27
Goldman Sachs
New York
| $1.24M | – | – | – |
|
|
DAM
28
DLD Asset Management
New York
| $1.04M | -$135K | -13,113 | -12% |
|
|
CS
29
Clear Street
New York
| $996K | +$1.2M | +116,407 | +56% |
|
|
WAM
30
Warberg Asset Management
Winnetka,
Illinois
| $955K | – | – | – |
|
|
PC
31
Periscope Capital
Toronto,
Ontario, Canada
| $519K | – | – | – |
|
|
32
JP Morgan Chase
New York
| $517K | -$515K | -49,869 | -50% |
|
33
Geode Capital Management
Boston,
Massachusetts
| $473K | – | – | – |
|
34
UBS Group
Zurich,
Switzerland
| $396K | +$186K | +18,038 | +90% |
|
|
DWM
35
Dakota Wealth Management
Palm Beach Gardens,
Florida
| $377K | – | – | – |
|
|
LPC
36
Lineage Point Capital
Palm Beach,
Florida
| $330K | +$329K | +31,840 | New |
|
|
HF
37
HRT Financial
New York
| $293K | +$8.21K | +795 | +3% |
|
|
LSC
38
Logan Stone Capital
Chicago,
Illinois
| $113K | +$113K | +10,900 | New |
|
39
Morgan Stanley
New York
| $1.25K | +$919 | +89 | +278% |
|
|
SIM
40
Sandia Investment Management
Boston,
Massachusetts
| – | -$161K | -15,721 | Closed |
|
DMAA Hedge Fund Activity: Q4 2025 in Review
39 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q4 2025, worth a combined $232M — up 3.9% from $223M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMAA positions and 1 closed out — a net gain of 3 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Mercuria Capital Strategies, opening a new position worth an estimated $7.74M. The largest seller was Polar Asset Management Partners, cutting an estimated $3.1M.
- 39 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $232M of Drugs Made In America Acquisition Corp stock for Q4 2025, up 3.9% quarter-over-quarter.
- 4 funds opened new Drugs Made In America Acquisition Corp positions in Q4 2025 and 1 closed out, a net change of +3 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q4 2025 was Mercuria Capital Strategies, an estimated $7.74M added.
- The largest Drugs Made In America Acquisition Corp seller in Q4 2025 was Polar Asset Management Partners, an estimated $3.1M sold.
Based on aggregated 13F filings for Q4 2025.